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Opinion statement
Neuromyelitis optica and neuromyelitis optica spectrum disorder (NMO/NMOSD) is a
rare but clinically aggressive demyelinating disease of the central nervous system
(CNS) caused by antibodies against water channel protein aquaporin 4 (AQP4) in the
astrocytic foot processes. Patients typically present with optic neuritis (ON) or
longitudinally extensive transverse myelitis (LETM). The majority of patients with
NMOSD show good response to treatment with steroids and plasmapheresis in the
acute setting; however, 90 % of patients will eventually have clinical relapses and
accrue permanent disability. Currently, immune modulation is the mainstay of main-
tenance therapy with anti CD-20 (rituximab, Rituxan™) having collectively the
strongest evidence to support its use and mycophenolate mofetil having comparable
reductions in absolute relapse rate (ARR) and expanded disability status scale (EDSS)
scores. Azathioprine, mitoxantrone, and methotrexate also have retrospective case
series data that demonstrate reduction in ARR and stabilization of EDSS but with
higher relapse rates and exposure to greater risk of treatment toxicities. Excitingly,
multiple novel therapies are under clinical study for patients who are refractory to
these first-line therapies including monoclonal antibodies targeting interleukin-6 (IL-
6), CD19, CD20, complement, and neutrophil elastase inhibitors which may provide
additional options for patients with severe clinical presentations. Importantly, no
randomized clinical trials have been published to date comparing clinical outcomes
of different maintenance therapies in NMOSD. Several trials are currently underway,
and results will help guide future management decisions as current evidence is from
many small, retrospective case series and cohort studies with many potential
confounds.
Multiple Sclerosis and Related Disorders (P Villoslada, Section Editor)
Introduction
Clinical presentation and epidemiology
Neuromyelitis optica spectrum disorder (NMOSD), for-
merly referred to as neuromyelitis optica (NMO) or
Devic’s disease, is a demyelinating disorder thought to
be caused by immunoglobulin G (IgG) antibodies
targeting water channel protein aquaporin 4 (AQP4)
located in astrocytic foot processes contributing to the
formation of blood-brain barrier (BBB) [1]. Incidence of
NMO is estimated at 0.05–4.4 per 100,000 with a 3:1–
9:1 female predominance and typically presents in the
third to fourth decade [2•]. The disease is more com-
monly seen among patients of Asian, African, and His-
panic ancestry; however, NMO occurs worldwide [3].
Clinical presentation most commonly consists of optic
neuritis (ON), longitudinally extensive transverse mye-
litis (LETM) (93 vertebral segments), or with an area
postrema syndrome (APS). However, brain lesions are
also seen in 60 % of patients, typically in periventricular
locations along the third or fourth ventricles, in the
thalamus, hypothalamus, or corpus callosum [4••].
It is of great importance to clinically differentiate
NMO from more common demyelinating disorders
such as multiple sclerosis (MS), as immunomodulatory
therapies for MS including interferon-beta (IFN-β),
glatiramer acetate, and natalizumab have been shown
to be ineffective and, in some cases, harmful [4••].
Instead, immunosuppression with agents such as ritux-
imab, mycophenolate mofetil (MM), and azathioprine
(AZT) are considered first-line therapies as will be fur-
ther described. Initiation of immune modulation is of
paramount importance since 90 % of patients with
NMOSD will relapse after initial presentation; 60 % will
relapse in the first year [2•]. With each attack, patients
acquire increasing levels of disability and often experi-
ence less recovery of function compared to patients with
MS. Indeed, if untreated for 5 years, 50% of patients will
be wheelchair bound and functionally blind. With cur-
rent treatments, at 5 years, 28 % require a cane to am-
bulate and less than 8 % are wheelchair bound [2•].
Diagnostic criteria
Clinical diagnosis of NMO is based on international
consensus diagnostic criteria that were published by
Wingerchuk and colleagues earlier this year that can be
met independent of AQP4 antibody positivity. If AQP4
IgG positive, a patient can meet criteria for NMO if at
least one core clinical criteria is met (optic neuritis, acute
myelitis, area postrema syndrome, acute brainstem
syndrome, narcolepsy or diencephalic syndrome, or ce-
rebral syndrome) with exclusion of alternative diagno-
ses to explain presentation. If AQP4 IgG negative, a
diagnosis of NMO may be made with the presence of
two of these core clinical criteria (one of which must be
ON, LETM, or APS) with imaging appearance clinically
consistent with NMO and without another alternative
diagnosis to better explain presentation [4••]. These
guidelines recommend that the term NMO be changed
to NMOSD to be inclusive of patients with NMO fea-
tures that may not be AQP4 IgG positive or may have
presentations outside of the common ON and LETM
presentations.
Despite these recently published recommendations,
the 2006 Wingerchuk criteria continue to be used in
ongoing research studies. According to these criteria, a
definite diagnosis of NMO may be given if a patient
presents with ON, acute myelitis, and at least two of
three supportive criteria (transverse myelitis ≥3 vertebral
segments, MRI brain not meeting diagnostic criteria for
MS, and AQP4 IgG positivity [5]. Thus, NMOSD is a
more inclusive term encompassing patients with fea-
tures of NMO regardless of antibody status as well as
those presenting with brainstem or brain lesions that are
not encompassed by the 2006 criteria.
Antibody markers
Anti-AQP4 antibodies are typically found in approxi-
mately 70 % of patients and screening assays are highly
specific for the disorder, but with imperfect sensitivity
estimated between 54 and 77 %, with higher sensitivity
with newer cell-based assays [6]. AQP4 IgG seropositiv-
ity is associated with a more severe disease course and
higher risk of relapses [3]. Antibodies to myelin oligo-
dendrocyte glycoprotein (MOG) were present in 7.4 %
of patients in a sample of 215 patients and were as a
group younger, more likely to be male, to have a
monophasic clinical presentation and to have better
functional recovery [7]. Oligoclonal bands can also be
helpful in differentiating NMOSD from MS as they are
uncommon in NMO but can be seen in up to 20 % of
patients [4••].
Pathogenesis
As opposed to MS, the pathogenesis of NMO is mediat-
ed by the humoral immune system. Anti-AQP4 antibod-
ies were identified in 2004 that bind to water channels
located in astrocytic foot processes, the gray matter of
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the central spinal cord, and along periaqueductal and
periventricular regions [1, 8, 9]. The distribution of
AQP4 channels is correlated with common sites of dis-
ease activity in NMO, and experiments have demon-
strated loss of AQP4 reactivity in active lesions which is
thought to be caused by endocytosis of the AQP4
homotetramer after antibody binding [8]. AQP4 anti-
bodies fix and activate complement which causes in-
flammation and tissue damage leading to disruption of
the BBB, edema, and secondary demyelination [9]. In
rats with experimental autoimmune encephalitis (EAE),
administration of recombinant anti-AQP4 antibodies
resulted in destruction of perivascular astrocytes and
deposition of perivascular IgG and complement as is
seen in humans, providing additional evidence for the
role of AQP4 antibodies in the pathogenesis of NMO
[10].
Understanding of this pathophysiology has led
to treatments which target humoral immunity in-
cluding monoclonal antibodies against B cells, ri-
tuximab, as well as more novel targets that are
currently being investigated including antibodies
against AQP4 antibody itself, neutrophil elastase,




The mainstay of acute treatment for NMOSD is high-dose corticosteroids,
typically solumedrol 1000mg for 3–5 days based on standard therapy for other
acute clinical presentations of demyelination. Corticosteroids mechanistically
cause immunosuppression and anti-inflammation by decreasing peripheral
lymphocytes, reducing inflammatory cytokines, and altering trafficking of leu-
kocytes [11]. Solumedrol is generally well tolerated in a short-term setting, but it
is important to provide ulcer prophylaxis and monitor for common psychiatric
side effects including insomnia and agitation.
Plasmapheresis
Patients who do not clinically respond to an initial steroid pulse should be
offered plasma exchange (PLEX) for five treatments, typically performed every
other day. Some recent publications have advocated that PLEX be offered along
with corticosteroids initially, especially in patients who present with relapse
with prior response to PLEX [12]. Bonnan and colleagues retrospectively com-
pared EDSS scores in 96 patients with NMO who received either steroids or
steroids plus PLEX between 1982 and 2008 and found that the change in their
EDSS at time of relapse compared 6months after presentationwas by 2.6 points
in patients who received steroids plus PLEX versus 1.2 in patients who received
steroids alone (PG0.01) [13]. Other case series also report a clinical benefit from
PLEX [14], and a recent comparison of steroids and steroids plus PLEX by
Abboud and colleagues in 16 patients with NMO relapse showed 65 % of
patients receiving steroids plus PLEX had a stable or improved EDSS post-
relapse compared to only 35% of patients who were treated with steroids alone
[12].
Maintenance therapies
Unlike MS, patients with NMO do not clinically respond to immunomodula-
tory therapies and may actually be harmed by their use [15, 16]. Instead,
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maintenance therapy is aggressively pursued through a number of immuno-
suppressant therapies,most commonly rituximab,MM, and AZT. At present, no
randomized clinical trials have been performed to compare different immu-
nosuppressive agents in terms of efficacy and current data is mostly limited to
retrospective case series. Thus, clinical practice varies greatly in terms of region
and practitioner experience.
Two recent studies allow for some limited comparisons of these agents.
Mealy and colleagues performed a retrospective study comparing annual re-
lapse rates (ARRs) in 90 patients receiving rituximab, MM, or AZT. Both MM
and AZT patients received concomitant treatment with prednisone. On rituxi-
mab, median ARR decreased from 2.61 to 0.33 with 2/3 of patients achieving
complete remission. On MM, median ARR decreased from 2.61 to 0.33 with
2/3 of patients also achieving complete remission. Overall, there was no sta-
tistically significant difference between ARR in patients treated with rituximab
and MM, but both were superior to AZT [17••]. Another study by Torres and
colleagues looked retrospectively at 71 patients with NMOSD to compare
rituximab, MM, AZT, and cyclophosphamide with rituximab showing the
greatest reduction in ARR (1.17 to 0.25, PG0.01) but powered only to detect
statistically significant differences in rituximab and AZT groups. Additionally,
50 % of patients receiving rituximab became remission free [18•].
These studies are limited by retrospective, case series design, small sample
size, and multiple confounders. Head-to-head randomized trials to compare
these agents are needed in the future as agents vary greatly in terms of cost.
Please refer to Table 1 for a summary of common medications used in chronic
management of NMOSD including dosing and side effects. Figure 1 summa-
rizes our recommended treatment algorithm based upon current literature.
Rituximab
Rituximab is a chimeric murine/human monoclonal antibody directed
against CD20 antigen on B cells and precursor B cells. The first case
series reporting benefit with use of rituximab in NMO patients was
published by Cree in 2005 and noted a statistically significant reduction
in the ARR from 2.6 to 0 in eight patients with 75 % of these patients
remaining relapse free at 12 months. EDSS significantly decreased from
7 to 5.5 as a proxy for patient’s functional status [19]. This initial study
was followed by multiple retrospective studies of various sizes demon-
strating reduction in ARR and stabilization or improvement of EDSS
with follow-up between 19 and 60 months [20, 21••, 22, 23].
Of note, each study used a different regimen in terms of induction
and maintenance dosing as well as different parameters for timing of
maintenance dosing. Regimens were based on either protocols for lym-
phoma or prior trials in MS. Interestingly, a small study in China of five
patients reported that a dose of rituximab 100 mg for 3 weeks with
repeat dosing when CD 19 cells 91 % (typically around 20 weeks)
allowed all patients to remain remission free which begs the question of
what an ideal therapeutic dose of rituximab should be, particularly given
its high cost [22]. Kim et al. suggest that redosing should occur with
rising of CD27+ memory B cells above 0.05 % in the first year of
therapy and above 0.1 % thereafter as their peripheral depletion has
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Curr Treat Options Neurol (2015) 17: 48 Page 5 of 14 48
been associated with clinical response to rituximab, but again larger
studies examining these questions with randomized design are needed
[21••].
Standard dosage Induction with either 1000 mg weekly for 2 weeks or 375 mg/m2 weekly for
4 weeks followed bymaintenance dose of either 375mg/m2 or 1000mgweekly
for 2 weeks when CD19 count 91 % on flow cytometry
Contraindications Severe liver disease, history of PML or prior chemotherapy
Main side effects Sepsis, infections including Herpes zoster, UTIs, URIs, leukopenia, transami-
nase elevation, PML is rare
Special points Cell counts should be monitored with flow cytometry every 3–6 months with
additional maintenance dose given for CD19 count 91 %
Cost/cost-effectiveness Expensive, approximately $27,000 per year
Fig. 1. Treatment algorithm for acute and chronic management of NMOSD.
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Mycophenolate mofetil
Mycopehnolate is a reversible inhibitor of inosine monophosphate dehydro-
genase, an enzyme needed for synthesis of guanosine, and acts as an immuno-
suppressant by impairing B and T cell synthesis. As noted in the above studies,
its reduction of ARR and EDSS are comparable to rituximab [17••]. A retro-
spective cohort of 24 patients was treated with 2000mg daily with concomitant
steroids resulted in a statistically significant reduction of ARR from 1.28 to 0.09
with stabilization or improvement in EDSS in 91 % of patients [24]. Twenty-
five percent of patients experienced an adverse effect.
Standard dosage 1000–2000 mg daily with concurrent prednisone (5–60 mg daily)
Contraindications Allergy to medication
Main side effects Photosensitivity, recurrent infections, headache, constipation, abdominal pain
leukopenia, PML is rare
Special points Goal absolute lymphocyte countG1500, should monitor CBC every 1–
3 months
Cost/cost-effectiveness $2000 per year
Azathioprine
AZT is a thiopurine antagonist of endogenous purines in DNA and RNA and
interferes with lymphocyte proliferation. AZT is one of the first-line immuno-
suppressant agents used for relapse prevention in NMOSD as well as many
other autoimmune disorders. Multiple retrospective cohort studies have exam-
ined the efficacy of AZT in terms of ARR and EDSS with one study in 2015
showing a reduction of ARR from 0.92 to 0.56 in 22 patients with 32 % of
subjects remaining relapse free [18•]. Another study in 2014 of 32 patients
showed reduction of ARR by 72 %, but with over half of subjects continuing to
have clinical relapses, which was inferior to outcomes on both rituximab and
MM [17••]. Elsone and colleagues examined a sample of 103 patients treated
with AZT and concomitant steroids with a statistically significant reduction of
ARR from 1.5 to 0. Sixty percent of patients remained relapse free at 18 months,
and EDSS stabilized or improved in 78 % [25]. A 2011 study by Costanzi and
colleagues showed AZT +/− steroids led to a reduction in ARR from 2.19 to 0.64
over 22 months but with only 37 % of patients remaining relapse free [26].
Thus, AZT with initial concurrent steroids is a cost-effective alternative for
immunosuppression in some patients but with higher risk of relapse.
Standard dosage 2–3 mg/kg/day with concomitant prednisone (5–60 mg daily) for 6–12 months
Contraindications Pregnancy, history of treatment with another alkylating agent, prior history of
lymphoma
Main side effects Nausea, diarrhea, rash, recurrent infections, leukopenia, transaminase eleva-
tion, increased risk of lymphoma
Special points Typically start with a dose of 25 mg daily and titrate gradually to goal, can take
6 months to become biologically active so concomitant steroids needed during
this period. Need to check thiopurine methyltransferase (TMPT) levels. If low,
need to reduce dose by 50 % because of increased risk of myelosuppression.
Monitor with monthly CBC.
Cost/cost-effectiveness $2000 per year
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Mitoxantrone
Mitoxantrone is an anthracenedione antineoplastic agent that works by inter-
calating with DNA, causing cross-linking and strand breaks and inhibits DNA
repair by interference with topoisomerase I. Specifically, it inhibits migration of
lymphocytes and decreases production of pro-inflammatory cytokines such as
IL-2, TNF-alpha, and IFN-gamma which inhibit B cell function [27].
Two studies have examined its clinical efficacy inNMO for relapse prevention.
The first was performed by Kim and colleagues and demonstrated a reduction of
ARR from 2.8 to 0.7 in 20 patients with half of patients becoming relapse free
[27]. No significant adverse effects were noted in this population. A second study
in 2012 by Cabre and colleagues showed a statistically significant reduction in
ARR from1.82 to 0.37 over 5 years of follow-upwith 32% remaining relapse free
at 5 years [28]. In this study, one patient developed mild CHF and one patient
was diagnosed with AML leading to discontinuation of the drug in both cases.
Standard dosage 12mg/m2 for 3–6 smonths, then 6–12mg/m2 every 3months formaintenance
Contraindications History of heart failure, leukemia, existing myelosuppression, hepatic impair-
ment, pregnancy, renal disease
Main side effects Nausea, transaminase elevation, leukopenia, hair loss, amenorrhea, minor
infections including UTI and URI, rarely heart failure and acute leukemia
Special points Should obtain baseline CBC, LFTs, uric acid level, and TEE prior to initiation of
therapy. TEEs should be monitored prior to any maintenance dose to monitor
LVEF and should continue to be monitored after discontinuation of therapy
because of possibility of delayed cardiotoxicity.
Cost/cost-effectiveness $4000 per year
Methotrexate
Methotrexate (MTX) is a folic acid antagonist that has been used as a mainte-
nance therapy for NMO at some centers, although there is not a significant
amount of data published on its use and outcomes. Kitley and colleagues
published a retrospective observational case series of 14 patients that received
MTX and steroids with reduction of ARR from 1.39 to 0.18 with stabilization of
EDSS in 79 % [29]. Additionally, Ramanathan et al. observed a statistically
significant reduction in ARR from 3.11 to 1.11 in 9 patients treated with MTX
for 18 months with stabilization of EDSS in 5 patients [30].
Standard dosage 7.5–15 mg per week with concomitant prednisone 5–60 mg daily for at least
6 months
Contraindications Liver disease, pregnancy, severe renal impairment
Main side effects Pneumonitis, GI upset, cytopenia, hepatotoxicity
Special points Obtain baseline CXR,monitor LFTs, CBC, and renal function; concomitant folic
acid therapy is required
Cost/cost-effectiveness Relatively inexpensive compared to other immunosuppressants
Cyclophosphamide
Cyclophosphamide is a cytotoxic alkylating agent that has been used in NMO
patients in two small clinical case series with contradictory findings. The first
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was of four Japanese patients with a reduction of EDSS from 8 to 5.75 after
receiving 500 mg/m2 after IV steroids and PLEX after an acute attack [31]. A
second study in 2012 showed no improvement in EDSS or ARR in seven
patients [32].
Standard dosage 1000 mg every 2 months with associated steroids
Contraindications Pregnancy, liver disease, prior hypersensitivity reaction
Main side effects Leukopenia, neutropenia, thrombocytopenia, arrhythmias, heart block, nau-
sea/vomiting, hepatic sinusoidal obstruction syndrome, hyponatremia, pneu-
monitis, hematuria, opportunistic infections.
Cost/cost-effectiveness $1400 per year
Emerging therapies
In addition to the above immunosuppressant agents, novel therapeutics
are currently undergoing investigation focusing upon multiple targets
that are based upon our ongoing understanding of pathogenesis of
NMOSD.
Tocilizumab
Tocilizumab is a human monoclonal antibody directed against the IL-6 recep-
tor and has been previously used in rheumatoid arthritis and juvenile idiopath-
ic arthritis. It is also currently used in NMOSD patients with aggressive presen-
tations that have been refractory to rituximab or other immunosuppression
[33]. Tocilizumab works by reducing plasmablast survival, thereby inhibiting
AQP4 Ab production. Previous studies have shown increased IL-6 levels in
serum and CSF of patients with NMO during relapses. The first published case
of its use in NMO was in 2013 by Araki and colleagues with a single patient
showing improvement in EDSS from 3.5 to 2 after four administrations [34].
This report was followed by a prospective pilot study of seven patients showing
an improvement in ARR from 2.9 to 0.4 [35]. Another small retrospective case
series of three patients saw similar improvement of ARR [36].
Most recently, a retrospective observational study of eight patients demon-
strated improvement of ARR from 4.0 to 0.4 after receiving monthly infusions
at doses of 6–8 mg/kg. All eight patients had experienced multiple relapses
despite treatment with rituximab. Relapses did occur in five of the patients, but
the majority occurred at a suboptimal dose or prolongation of the time interval
between subsequent doses [33]. Adverse effects included elevated cholesterol
levels, infections, venous thrombosis, and neutropenia.
Standard dosage 8 mg/kg every 4 weeks
Contraindications History of TB infection, liver disease, severe elevations in cholesterol, neutro-
penia, thrombocytopenia
Main side effects GI disturbance, fatigue, UTIs, neutropenia, leukopenia, elevation of cholesterol,
transient mild transaminase elevation, DVT, TB reactivation
Special points Monitor lipids, CMP, and CBC every 6weeks initially, then every 3months after
first 6 months of therapy. Need to initially screen for latent TB infection prior to
initiation.
Cost/cost-effectiveness $24,000 per year
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Eculizumab
Eculizumab is a humanized monoclonal antibody directed against C5 protein
which prevents its cleavage to C5a and C5b, the latter of which initiates the
cytolytic terminal membrane attack complex (MAC) of the complement cas-
cade. Complement deposition has been shown to be involved in the patho-
genesis of NMOSD with product deposition co-localizing in areas where AQP4
is normally distributed [8].
To date, only one small, prospective clinical trial has been performed with
eculizumab. Fourteen patients received 4 weeks of the drug initially and then
were maintained with infusions every 2 weeks thereafter for 48 weeks. All
remained relapse free at 1 year with the exception of two possible clinical
relapses. ARR was reduced from 3.0 to 0 and median EDSS improved from
4.3 to 3.5 overall with all patients showing stabilization or improvement of
their EDSS. Only one patient suffered an adverse effect of meningococcal sepsis
and sterile meningitis [37]. A major prohibitive factor in using this treatment is
its high cost relative to other therapies. A phase III open-label trial and ran-
domized, double-blinded clinical trial are currently underway.
Standard dosage IV 600 mg weekly for 4 weeks, then IV 900 mg every 2 weeks
Contraindications Unresolved Neisseria infection
Main side effects Headache, increased risk of infection with encapsulated organisms, especially
meningococcal infections
Special points Vaccinate with meningococcal vaccine at least 2 weeks prior to initiation
Cost/cost-effectiveness $400,000 per patient-year, $7333 per 30 mg vial
Aquaporumab
Aquaporumab is a nonpathogenic recombinant human monoclonal antibody
that is comprised of an Fc portion that tightly binds AQP4 and an Fc portion
that is mutated to lack the potential to activate complement and cellular
damage. In vivo and ex vivo experiments demonstrated that administration of
aquaporumab prevented development of NMO lesions in a mouse model [38].
The drug is still undergoing preclinical development but theoretically would be
an advantageous therapeutic target given lack of associated adverse side effects
unlike other immunosuppressive agents.
CD19-targeted therapies
Rituximab has strong evidence to support its use in prevention of relapses in
NMOSD, but up to 25–50 % patients continue to have clinical relapses despite
adequate suppression of CD19 count [17••, 18•, 21••]. CD19 is expressed on
plasmablasts responsible for AQP4 Ab production and their reconstitution after
administration of rituximab was shown to be correlated with increasing serum
AQP4 Ab levels [39]. Since an increase in CD19+ plasmablasts is correlated with
relapse, CD19 represents an alternative B cell target with potential to be used alone
or in conjunction with other monoclonal antibodies such as rituximab. Multiple
CD19-targeted therapies are currently under development and being studied as
treatments for leukemia (ALL and CLL), lymphomas (DLBCL, NHL), and auto-
immune diseases including rheumatoid arthritis and lupus but could be investi-
gated in NMOSD in the future [40].
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Complement inhibitor CD59
CD59 is a glycophosphoinositol (GPI)-anchored membrane protein on astro-
cytes that inhibits that terminal C5b-C9 membrane attack complex [41]. There
is current interest in studying upregulation of CD59 as a potential treatment for
NMO because of previous studies in mice suggesting inhibition of CD59 led to
worsening disease in NMO. In one study, murine astrocytes were exposed to
both anti-AQP4 and anti-CD59 antibodies with increased complement-
dependent cytotoxicity (CDC) to astrocytes in culture as well as ex vivo spinal
cord slices [42]. The study also reported extensive longitudinal spinal demye-
lination in CD59 knockoutmice thought to be related to increased CDC. CD59
pharmacological upregulation is not yet under clinical study in humans but
represents a novel therapeutic approach warranting further investigation.
Granulocyte-targeted therapies
Pathological studies of NMO lesions are notable for IgM, IgG, and complement
deposits that are co-localized in areas where AQP4 channels are typically found
and tend to be perivascular. Antibody-dependent astrocyte damage including
CDC leads to neutrophilic and eosinophilic inflammation [8]. Indeed, CSF of
patients with NMO can be notable for a cellular pleocytosis, typically of G50 cells
with neutrophilic and eosinophilic predominance [4••]. Several therapeutics are
currently in development that target cellular inflammation in NMO including
neutrophil elastase inhibitors and antihistamines.
Silvestat is a neutrophil elastase inhibitor that is involved in neutrophil migra-
tion and phagocytosis that is currently being used in Japan to treat acute respiratory
distress syndrome [43]. Neutrophil elastase has been shown, along with other
Th17 cytokines, to be elevated in patients with NMOSD [44]. The same authors
used a mouse model of EAE induced by T helper 17 (Th17) cells with inflamma-
tion targeting the optic nerves and spinal cord as is seen inNMOSD to demonstrate
that use of silvestat was correlated with reduced inflammatory infiltrates in both
spinal cord and optic nerves [44]. Another study by Saadoun and colleagues
observed reduced AQP4 loss and inflammation in neutropenic mice exposed to
human AQP4 IgG and an improvement in lesion burden in mice exposed to
intrathecal silvestat [45]. The authors postulate that silvestat could be helpful in
treatment of acute NMO attacks as it could prevent migration of neutrophils into
the CNS and thus prevent lesion formation.
Antihistamines, such as cetirizine, have also been found to reduce cytotox-
icitymediated by AQP4Ab and eosinophils in in vivo and ex vivomousemodels.
In a mouse model, those mice exposed to intracerebral injection of AQP4 Ab
and complement showed marked eosinophilic infiltration with lesions wors-
ened in transgenic hypereosinophilic mice and decreased lesion burden in
hypoeosinohilic mice (from gene deletion or exposure to IL-5) and in mice
exposed to cetirizine [46]. Thus, antihistamines that can stabilize eosinophils
may have future utility in treating NMOSD.
Conclusions
The current management of NMOSD entails acute treatment with IV steroids as
well as PLEX in patients without a significant response to steroids. Long-term
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management is important to prevent relapses and progression of disabil-
ity with rituximab, MM, and AZT being the most common immunosup-
pressant agents currently in use. Current data investigating ARR and
EDSS in patients taking immunosuppression is mostly limited to retro-
spective case series or cohort studies with limitations related to small
study design, exposure to other concurrent therapies, and lack of ran-
domization and control groups, but evidence is most supportive of
rituximab and MM in small comparison studies. Randomized clinical
trials including head-to-head comparisons of these medications are
needed in the future to help determine optimal choice of therapy,
particularly with varying cost of agents.
Excitingly, there are many emerging therapies currently under investigation
includingmonoclonal antibodies directed toward elements of the complement
cascade, IL-6, CD19+ plasma cells, and AQP4 itself, as well as therapeutics
targeting granulocytes involved in inflammation in NMO and complement
inhibitors. Development of a therapy with selective effect and reduced toxicity
will be a central goal of future investigation.
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